|Bid||461.03 x 900|
|Ask||461.66 x 900|
|Day's range||454.95 - 462.57|
|52-week range||418.01 - 664.64|
|Beta (5Y monthly)||0.16|
|PE ratio (TTM)||15.11|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. Regeneron Pharmaceuticals' fiscal 2020 performance has been quite remarkable, considering the many pressures it faced due to COVID-19 related restrictions. Regeneron's blockbuster retinal disease drug, EYLEA, continues to be a force to reckon with, clocking sales of $7.9 billion globally (in conjucnction with Bayer).
Cathie Wood, founder, CEO, and chief investment officer (CIO) of ARK Invest. Earlier this month, the ARK Genomic Revolution fund purchased more than 100,000 shares of Regeneron Pharmaceuticals (NASDAQ: REGN). Regeneron, maker of an antibody cocktail to treat COVID-19, is the fund's fourth-biggest holding.
Shares of Ocular Therapeutix (NASDAQ: OCUL) have more than tripled investors' money over the past year as the company's long-lasting eye treatments took big steps forward. Despite the big gains it's already produced, this soaring biotech stock hasn't reached a peak yet. Like most smart investment decisions, there's more than one good reason to buy Ocular Therapeutix at the moment.